Data on invasive cervical cancer (ICC) incidence in HIV-positive women and the effect of cervical cancer screening in subSaharan Africa are scarce. We estimated i) ICC incidence rates in women (18 years) who initiated antiretroviral therapy (ART) at the Themba Lethu Clinic (TLC) in Johannesburg, South Africa, between 2004 and 2011 and ii) the effect of a Pap-based screening program. We included 10,640 women; median age at ART initiation: 35 years [interquartile range (IQR) 30-42], median CD4 count at ART initiation: 113 cells/mL . During 27,257 person-years (pys), 138 women were diagnosed with ICC; overall incidence rate: 506/100,000 pys [95% confidence interval (CI) 428-598]. The ICC incidence rate was highest (615/100,000 pys) in women who initiated ART before cervical cancer screening became available in 04/2005 and was lowest (260/100,000 pys) in women who initiated ART from 01/2009 onward when the cervical cancer screening program and access to treatment of cervical lesions was expanded [adjusted hazard ratio (aHR) 0.42, 95% CI 0.20-0.87]. Advanced HIV/AIDS stage (4 versus 1, aHR 1.95, 95% CI 1.17-3.24) and middle age at ART initiation (36-45 versus 18-25 years, aHR 2.51, 95% CI 1.07-5.88) were risk factors for ICC. The ICC incidence rate substantially decreased with the implementation of a Pap-based screening program and improved access to treatment of cervical lesions. However, the risk of developing ICC after ART initiation remained high. To inform and improve ICC prevention and care for HIV-positive women in sub-Saharan Africa, implementation and monitoring of cervical cancer screening programs are essential.
adult women (15-49 years) have HIV, 9 ICC is the second most common cancer in women in the general population and the leading cause of cancer-related deaths. 10 The effect of antiretroviral therapy (ART) on the incidence of cervical lesions and ICC in HIV-positive women remains unclear.
11-14 On one hand, early initiation of ART may reduce the risk of coinfection with high-risk HPV types. 15 On the other hand, ART might lead to higher ICC incidence rates due to lower competing mortality from other HIV-related causes. 11 Therefore, effective cervical cancer screening programs are essential to lower ICC-related morbidity and mortality in HIV-positive women. 16 Because of the increased risk of developing ICC, more frequent cervical cancer screening is recommended for HIV-positive than for HIV-negative women. 17, 18 To inform cervical cancer screening programs for HIV-positive women in South Africa, data on ICC burden, associated risk factors, and the effect of screening programs on ICC risk in this specific population are needed. Whereas some ICC incidence rate estimates are available for HIV-positive women in sub-Saharan Africa, ranging from 8/100,000 pys to 259/100,000 pys, [19] [20] [21] [22] data on risk factors and the effect of cervical cancer screening on ICC risk are scarce for the African setting. Studies examining the effect of cervical cancer screening at the patient-level often do not have enough power to detect changes in ICC incidence rates. 13, 15 However, relevant information can also be obtained from using precancerous lesions as an end point. We estimated ICC incidence rates in HIV-positive women who initiated ART at the Themba Lethu Clinic (TLC) in Johannesburg, South Africa, identified risk factors for developing ICC in these women and assessed the effect of the introduction and expansion of a Papanicolaou (Pap) smear-based cervical cancer screening program on ICC incidence rates.
Methods

Study site and data sources
The TLC in Johannesburg, South Africa, was established in 1992 to provide care for HIV-positive adults living in the area. It is a government clinic, but also receives financial support from Right to Care, a South African nonprofit organization, which is partly funded by the United States Agency for International Development (USAID) and the President ' 18 Pap tests are supposed to be repeated every 3 years if cytology results are normal and after 1 year if a low-grade cervical squamous intraepithelial lesion is detected in HIV-positive women. Women with highgrade intraepithelial lesions are supposed to be referred for colposcopy. In 2011, data from the TLC cohort were linked to the South African National Cancer Registry (NCR) database to complete cancer case recording for patients enrolled in the TLC cohort. The NCR is pathology-based and collects information on histologically, cytologically or hematologically confirmed cancer cases from both public and private laboratories all over South Africa. The record linkage was probabilistic and based on first name, second name, surname, date of birth and gender. Data from the cancer registry were available up to August 2011. To minimize the risk of mismatches cancer cases identified through the probabilistic record linkage with the NCR were cross-checked for plausibility with patient files from the TLC. The TLC cohort has an on-going ethics approval (M140201) from the Human Research Ethics Committee (Medical) (HREC) of the University of the Witwatersrand to analyze routine clinical data, and this approval is renewed annually. The record linkage between the TLC cohort database and the NCR in South Africa was based on an additional HREC-approved protocol (M110324 (PIs) . Regimens consisting of two NRTIs and one NNRTI were classified as NNRTI-based, regimens consisting of two NRTIs and one PI (with or without ritonavir as a booster) were classified as PI-based. Women were assumed to stay on ART once started. CD4 cell counts at ART initiation were defined as the measurement closest to the date of ART initiation, within 90 days before to 7 days after ART initiation. Nadir CD4 was defined as the lowest ever measured CD4 cell count before ICC diagnosis. ICC cases diagnosed before or at start of ART were excluded as prevalent cases, whereas ICC cases diagnosed after ART initiation were analyzed as incident cases.
Statistical analyses
We calculated ICC incidence rates by dividing the number of women who were diagnosed with ICC after ART initiation by the total person-time at risk. Time at risk was measured from ART initiation to ICC diagnosis, last follow-up visit, death or database closure, whichever occurred first. We calculated ICC incidence rates for the whole observation time, but also separately for different time periods after ART initiation (0 to 1, >1 to 3 and >3 years after ART initiation). We computed agestandardized ICC incidence rates using the world standard population proposed by Segi 24 and adapted by Doll et al. 25 As our study population did not include children and only few elderly women, we assumed that all women aged 60 years had the same ICC incidence rate and that children had an ICC incidence rate of zero. In a sensitivity analysis, we restricted the world standard population to adults. We examined potential risk factors for incident ICC using crude and adjusted Cox proportional hazards models. We explored the following potential risk factors: age at ART initiation (18-25, 26-35, 36- . As women with prevalent ICC were excluded from the analysis, WHO stage 4 at ART initiation was based on other stagedefining comorbidities than ICC. We also included CD4 cell counts as spline variables in the model. The multivariable Cox model included all variables that were significantly or borderline significantly associated with ICC risk in univariable analyses, that is age at ART initiation, first-line ART regimen, calendar period of ART initiation and WHO clinical stage of HIV/AIDS at ART initiation. The significance level was set at p values < 0.05 for all hypothesis tests. In sensitivity analyses, we excluded ICC cases diagnosed within 6 months after ART initiation and women with less than 6 months of follow-up to reduce potential misclassification of prevalent ICC cases as incident ICC cases, and we used multiple imputations for missing data on CD4 cell counts and WHO stage of HIV/AIDS at ART initiation. We used predictive mean matching and chained equations to create 20 imputed datasets. Results are presented as percentages, medians with interquartile ranges (IQR), incidence rates per 100,000 pys with 95% confidence intervals (CIs) or hazard ratios (HRs) with 95% CIs. All analyses were done in Stata 13.1 (Stata Corporation, College Station, TX).
Results
Study population
The TLC dataset included information on 13,383 HIVpositive women aged 18 years or older who initiated ART at the TLC between April 1, 2004, and August 31, 2011. Of these we excluded 1,936 women who started ART before enrollment into the cohort. Another 807 women were excluded for reasons detailed in Figure 1 . Excluded women were slightly younger (median age: 33 versus 35 years) and more likely to receive PI-based first-line ART regimens (14% versus 8%) than included women. Data on WHO clinical HIV/AIDS stage and CD4 cell counts at ART initiation were missing for the majority of excluded women (68% and 43%, respectively), but for <15% of included women, and could therefore not be compared.
We included data on 10,640 women; median age at ART initiation was 35 years (IQR 30-42 years), median CD4 cell count at ART initiation was 113 cells/mL (IQR 46-184 cells/ mL). Over calendar period, the median CD4 cell count at ART initiation increased from 82 cells/mL (IQR 36-143 cells/ , and most women (n 5 9,785; 92%) received an NNRTI-based first-line regimen. About half of the women were unemployed (53%, n 5 5,646) and the majority had never smoked (83%, n 5 8,823).
ICC incidence rates and risk factors
During a total of 27,257 pys, 138 women were diagnosed with ICC for an overall ICC incidence rate of 506/100,000 pys (95% CI 428-598). The age-standardized ICC incidence rate was 273/100,000 pys (95% CI 177-420) when including children and 396/100,000 (95% CI 256-614) when excluding children. Median follow-up time after ART initiation was 2.1 years (IQR 0.7-4.1 years), and median time to ICC diagnosis after ART start was 1.8 years (IQR 0.9-3.2 years). The ICC incidence rate did not change over time after ART initiation (Fig. 2) . The ICC incidence rate declined over calendar time of ART initiation: it was highest (615/100,000 pys) in women who initiated ART before Pap-based screening became available at TLC in April 2005, and it was lowest (260/100,000 pys) in women who initiated ART from 2009 onward when LEEP became available and Pap-based cervical cancer screening was expanded beyond TLC to other HIV clinics in the area (Table 1 ). No decrease in ICC incidence rates was apparent when we looked at calendar period of follow-up instead of calendar period of ART initiation. When we excluded the first 6 months of follow-up after ART initiation in a sensitivity analysis, the ICC incidence rate remained similar in the earlier calendar periods of ART initiation, but declined to 69/100,000 pys in the most recent calendar period of ART initiation (Supporting Information Table S1 ).
In univariable analyses, the risk of developing ICC was associated with calendar period of ART initiation (p 5 0.011), age at ART initiation (p 5 0.031), first-line ART regimen (p 5 0.003), and WHO clinical stage of HIV/AIDS at ART initiation (p 5 0.059, Table 1 ). However, CD4 cell count at ART initiation, nadir CD4 and current CD4 cell count had no effect on ICC risk in our analyses, neither as categorical variables nor as spline variables (data on file). We also did not find an association between ICC risk and calendar period 
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Discussion
The risk of developing ICC in women who initiated ART at the TLC in Johannesburg, South Africa, declined over calendar time of ART initiation with the introduction and expansion of Pap-based cervical cancer screening and treatment of cervical lesions. However, the ICC incidence rate in HIVpositive women on ART remained high even after the expansion of Pap-based cervical cancer screening to other HIV 
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clinics in the area. We found that advanced WHO clinical stage of HIV/AIDS at ART initiation was a risk factor for developing ICC. In contrast, time since ART initiation and nadir, baseline or current CD4 cell counts were not associated with the risk of developing ICC. Our study is one of the first to describe ICC incidence rates along with associated risk factors in HIV-positive women who initiated ART in sub-Saharan Africa, and the first one to evaluate the effect of the introduction of a Papbased cervical cancer screening program on ICC incidence rates in this setting. It is based on prospectively collected routine clinical data, and ICC ascertainment was improved through record linkage with the South African NCR. However, several limitations need to be addressed. Even after the record linkage with the pathology-based NCR, ascertainment of ICC cases is likely to be incomplete, resulting in an underestimation of the ICC risk in women who initiated ART. Lag times in cancer registration at the NCR might lead to some under-reporting of ICC cases in more recent calendar periods. The results we report for HIV-positive women attending one urban ART program in South Africa might not necessarily be generalizable to all HIV-positive women initiating ART in South Africa or to other ART programs with different cervical cancer screening practices. Cervical cancer screening and treatment status at patient-level was not available, and therefore we could not assess the effect of Pap-based cervical cancer screening on ICC incidence rates directly. Data on several potentially relevant risk factors, such as HIV RNA load, number of pregnancies, contraceptive use, number of sexual partners and condom use, were very limited or not available and could therefore not be analyzed. We assumed that women remained on ART once initiated and did not consider treatment interruptions and terminations. ICC incidence rates in women who are fully adherent to ART might be lower than what we report.
We found that the ICC incidence rate in our cohort decreased over calendar periods of ART initiation with the introduction of a screening program and early treatment of cervical lesions. We are not aware of other studies assessing ICC incidence rates before and after the introduction of a cervical cancer screening program in an ART program. However, Shiels et al. 26 showed that in HIV-positive women in the United States yearly ICC incidence rates declined steeply in the early 1990s before the advent of ART. This decline is most likely attributable to cervical cancer screening and improved treatment of precancerous cervical lesions. 27 Other studies in HIV-positive women, on the other hand, showed increasing ICC incidence rates over calendar periods. [28] [29] [30] Our study found a very high overall ICC incidence rate of >500/100,000 pys in HIV-positive women who initiated ART. Few other studies reported similarly high ICC incidence rates in HIV-positive women, 26, 28, 31 but most studies found substantially lower ICC incidence rates. [19] [20] [21] [22] 29, [32] [33] [34] [35] [36] For example, in a cohort of regularly Pap-screened HIV-positive women in the United States, the ICC incidence rate was as low as 12/100,000 pys. 36 Whereas well-established systematic screening programs might partly explain the lower ICC incidence rates in HIV-positive women living in high-income countries, the very low ICC incidence rates found in three sub-Saharan African record linkage studies are likely to be underestimations. [19] [20] [21] The more limited access to pathology services in Nigeria, Uganda and Malawi compared to South Africa might have resulted in more extensive under-diagnosis and under-reporting of ICC cases. 37 In general, ICC incidence rate estimates across studies need to be compared cautiously due to different study populations, settings, calendar periods and study designs.
Immunodeficiency measured as low CD4 cell count is the most extensively studied risk factor for ICC in HIV-positive women, and its effect on ICC risk remains controversial. We and others did not find an association with ICC risk, 29, 38 whereas some studies showed an increased ICC risk with lower CD4 cell counts at cohort enrollment 33 or during follow-up. 34 Interestingly, we found that advanced WHO clinical stage of HIV/AIDS as a measure of immunodeficiency at ART initiation was a risk factor for developing ICC, but Mbulaiteye et al. 20 did not find such an association. As in other studies, we also observed that ICC risk was highest in middle-aged women. 20, 33, 34 In our analysis, women who received PI-based regimens tended to have a lower risk of developing ICC than women who received a standard NNRTI-based regimen. In vitro studies have suggested that some PIs might have antitumor effects against cervical cancer cells. 39, 40 However, as the treatment allocation was not randomized in our study, this finding should be interpreted with caution.
Before cervical cancer screening was introduced at TLC ICC incidence rates in HIV-positive women who had initiated ART were very high. After the introduction of cervical cancer screening and early treatment of cervical lesions at the TLC and expansion to other HIV clinics in the area ICC risk declined. We did not observe a decline in ICC incidence rates by time since ART initiation. However, most women in our cohort initiated ART at low CD4 cell counts, and the follow-up time of our study might not have been long enough to detect a protective effect of ART on ICC development. 15 Besides efforts to grant universal access to prompt ART initiation, effective and wide-spread cervical cancer screening programs are needed to lower ICC-related morbidity and mortality. Different screening approaches including Pap smears, HPV testing and visual inspection with acetic acid and Lugol's iodine are available. 41 To determine the best screening approach for a given setting, available resources and cost-effectiveness need to be taken into account. 42 Irrespective of the screening method chosen, adequate infrastructure, trained personnel and access to early treatment of cervical lesions are essential to ensure effectiveness. 43 In addition, rigorous monitoring of cervical cancer screening programs is needed to continuously improve and maintain patient outcomes. 43 Large-scale studies analyzing temporal trends in ICC incidence rates are important because they have sufficient power to evaluate ICC directly as the outcome of interest. However, without patient-level data on screening and treatment of cervical lesions, it is not possible to determine the extent to which interventions such as a screening program have directly impacted on outcomes, nor to understand observed ICC incidence rates in context, and to prioritize targets for further intervention. Therefore, observational HIV cohorts routinely collecting patient-level data on cervical cancer screening status and treatment of cervical lesions can offer critical evidence toward understanding ICC and should be prioritized in future evaluations.
With the implementation of a Pap-based screening program and improved access to treatment of cervical lesions the incidence rate of ICC substantially decreased in HIVpositive women who initiated ART. However, the risk of developing ICC after ART initiation remained high. To inform ICC prevention and care for HIV-positive women, implementation and thorough monitoring of cervical cancer screening programs in sub-Saharan Africa are essential.
